OncoCyte Co. (NASDAQ:OCX) CEO Josh Riggs Acquires 3,390 Shares

OncoCyte Co. (NASDAQ:OCX) CEO Josh Riggs bought 3,390 shares of the company’s stock in a transaction on Thursday, April 11th. The shares were acquired at an average price of $2.95 per share, with a total value of $10,000.50. Following the completion of the acquisition, the chief executive officer now directly owns 3,505 shares in the company, valued at approximately $10,339.75. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link.

OncoCyte Stock Up 8.7 %

OncoCyte stock opened at $2.75 on Wednesday. OncoCyte Co. has a 12-month low of $2.08 and a 12-month high of $6.80. The firm’s 50-day moving average is $2.96 and its two-hundred day moving average is $3.06.

Institutional Investors Weigh In On OncoCyte

Several hedge funds have recently modified their holdings of OCX. Millennium Management LLC acquired a new stake in shares of OncoCyte in the second quarter worth approximately $896,000. Geode Capital Management LLC boosted its position in shares of OncoCyte by 23.8% in the second quarter. Geode Capital Management LLC now owns 1,228,553 shares of the company’s stock worth $283,000 after acquiring an additional 236,099 shares during the last quarter. Vanguard Group Inc. boosted its position in shares of OncoCyte by 2.3% in the first quarter. Vanguard Group Inc. now owns 3,986,270 shares of the company’s stock worth $5,940,000 after acquiring an additional 90,534 shares during the last quarter. Goldman Sachs Group Inc. boosted its position in shares of OncoCyte by 17.8% in the second quarter. Goldman Sachs Group Inc. now owns 541,983 shares of the company’s stock worth $487,000 after acquiring an additional 81,979 shares during the last quarter. Finally, Renaissance Technologies LLC boosted its position in shares of OncoCyte by 131.7% in the second quarter. Renaissance Technologies LLC now owns 138,100 shares of the company’s stock worth $32,000 after acquiring an additional 78,500 shares during the last quarter. 55.35% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on OCX shares. StockNews.com started coverage on shares of OncoCyte in a research note on Friday, April 12th. They set a “sell” rating on the stock. Benchmark reaffirmed a “speculative buy” rating and set a $5.00 price target on shares of OncoCyte in a research note on Monday.

OncoCyte Company Profile

OncoCyte Corporation, a molecular diagnostics company, research, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay.